The Use of Extracellular Vesicles as Drug Carriers

Jack Rubin^*
*Correspondence: Jack Rubin, Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland, Email:

Introduction

The development of novel drug delivery systems is crucial to enhance the efficacy and reduce the side effects of therapeutic agents. One such promising approach is the utilization of Extracellular Vesicles (EVs) as drug carriers. EVs are small lipid-bound vesicles released by various cell types, playing essential roles in cell-to-cell communication and cargo transportation. Over the past few years, the potential of EVs as drug delivery vehicles has garnered significant attention from researchers and pharmaceutical industries alike. This article aims to explore the characteristics of EVs, their potential applications in drug delivery, and the challenges and future prospects of using EVs as drug carriers. Extracellular vesicles are a heterogeneous group of membrane-enclosed vesicles secreted by cells into the extracellular environment. They can be broadly classified into three main types based on their biogenesis: exosomes, microvesicles (also known as ectosomes or shedding vesicles), and apoptotic bodies. The primary source of exosomes is the endosomal pathway, where intraluminal vesicles are formed within Multivesicular Bodies (MVBs) and later released upon fusion with the plasma membrane. Microvesicles, on the other hand, bud directly from the cell membrane. Apoptotic bodies are produced during apoptosis and contain cellular components [1].

EVs are abundant in various body fluids, such as blood, urine, saliva, and breast milk, making them readily accessible for therapeutic purposes. Their sizes typically range from 30 to 150 nm for exosomes and 100 to 1,000 nm for microvesicles, which allows them to efficiently traverse biological barriers and deliver cargo to target cells. One of the primary advantages of using EVs as drug carriers is their ability to encapsulate various therapeutic agents, including small molecules, nucleic acids, proteins, and even nanoparticles. The cargo-loading process can be achieved through several methods, such as electroporation, sonication, incubation, or genetic engineering of producer cells. These techniques allow for efficient and controlled loading of therapeutic agents into EVs, ensuring stability and protection of the cargo from degradation [2].

EVs can be engineered to display specific targeting ligands on their surface, facilitating targeted drug delivery to specific tissues or cells. By modifying the surface proteins of EVs, researchers can enhance their tropism to diseased tissues, leading to improved therapeutic outcomes and reduced off-target effects. Moreover, EVs possess natural homing abilities, as they can be taken up by cells expressing cognate receptors, making them ideal vehicles for targeted drug delivery. EVs are derived from natural cellular processes, making them biocompatible and less likely to trigger adverse immune responses. Unlike synthetic drug carriers, such as liposomes or polymeric nanoparticles, EVs are composed of endogenous lipids and proteins, reducing the risk of immune system recognition and rejection. This inherent biocompatibility is a significant advantage when considering their clinical translation. EVs can extend the circulation time of therapeutic agents in the bloodstream, increasing their bioavailability and reducing the need for frequent dosing. The lipid bilayer of EVs provides protection to the encapsulated cargo from enzymatic degradation and clearance by the reticuloendothelial system, resulting in prolonged systemic exposure. EVs can efficiently penetrate cell membranes due to their origin and natural role in cell communication. As drug carriers, they can deliver their cargo directly to the cytoplasm or nucleus of target cells, facilitating drug uptake and enhancing therapeutic efficacy [3].

The use of EVs as drug carriers holds great promise in cancer therapy. EVs derived from specific cell types, such as dendritic cells or mesenchymal stem cells, can be loaded with anticancer agents, small interfering RNA (siRNA), or microRNA to target tumor cells. These engineered EVs can bypass the bloodbrain barrier and deliver drugs to brain tumors, opening up new possibilities for treating otherwise challenging conditions. Neurological disorders, such as Alzheimer's and Parkinson's disease, present significant challenges for drug delivery due to the limited access of therapeutics to the brain. EVs can cross the blood-brain barrier and deliver therapeutic agents, including small molecules and nucleic acids, to affected neurons, potentially slowing disease progression and promoting neuroprotection.

Description

In regenerative medicine, EVs derived from stem cells can be harnessed for their regenerative and reparative properties. These EVs carry a payload of growth factors and cytokines that can promote tissue repair and regeneration. By delivering EVs to the site of injury, researchers aim to stimulate tissue healing and recovery. One of the key challenges in using EVs as drug carriers is the scalability of production. Current isolation methods can be time-consuming, expensive, and yield low quantities of pure EVs. Overcoming these challenges will be critical to enable large-scale production for clinical applications.

The field of EV research faces standardization and characterization challenges. The heterogeneity of EV populations and variability in cargo composition require standardized isolation and characterization methods to ensure consistent drug delivery performance and reproducibility. As EV-based therapeutics move closer to clinical applications, regulatory approval and safety concerns become paramount. Robust preclinical studies and a thorough understanding of potential side effects and long-term consequences of EVbased therapies are essential for their successful translation [4,5].

Conclusion

Extracellular vesicles offer a promising platform for drug delivery, harnessing their natural characteristics to efficiently transport therapeutic agents to target cells. The use of EVs as drug carriers has the potential to revolutionize medicine by improving treatment efficacy, reducing side effects, and enabling targeted therapies for various diseases. Despite the challenges ahead, ongoing research and advancements in EV isolation, loading techniques, and standardization will likely lead to exciting breakthroughs and widespread clinical use in the future.

Acknowledgement

None.

Conflict of Interest

There is no conflict of interest by author.

References

1. Szwedowicz, Urszula, Zofia Łapińska, Agnieszka Gajewska-Naryniecka and Anna Choromańska. "Exosomes and other extracellular vesicles with high therapeutic potential: Their applications in oncology, neurology and dermatology."Molecules27 (2022): 1303.

Google Scholar, Crossref, Indexed at

2. Willms, Eduard, Carlos Cabañas, Imre Mäger and Matthew JA Wood, et al. "Extracellular vesicle heterogeneity: Subpopulations, isolation techniques and diverse functions in cancer progression."Front Immunol 9 (2018): 738.

Google Scholar, Crossref, Indexed at

3. Théry, Clotilde, Armelle Regnault, Jérôme Garin and Joseph Wolfers, et al. "Molecular characterization of dendritic cell-derived exosomes: Selective accumulation of the heat shock protein hsc73."J Cell Biol 147 (1999): 599-610.

Google Scholar, Crossref, Indexed at

4. Gross, Julia Christina, Varun Chaudhary, Kerstin Bartscherer and Michael Boutros. "Active wnt proteins are secreted on exosomes."Nat Cell Biol 14 (2012): 1036-1045.

Google Scholar, Crossref, Indexed at

5. Herrmann, Inge Katrin, Matthew John Andrew Wood and Gregor Fuhrmann. "Extracellular vesicles as a next-generation drug delivery platform."Nat Nanotechnol 16 (2021): 748-759.

Google Scholar, Crossref, Indexed at